Category Reviews

Much of the policy-making conversation about health care in recent years has sought to highlight anticipated cost savings from technology innovation. Critics say this is an outgrowth of the American "fix-it" mentality. Others say technical solutions have yet to take hold outside of medical accounting applications. But there is general agreement that in the area of technologies to nurture medication adherence, the ground remains fertile.

It's been long accepted that politics makes strange bedfellows. That's certainly the case with the reauthorization in 2012 of the Prescription Drug User Fee Act.

Canadian generic drug makers expressed dismay over a new plan to reduce reimbursements for a half-dozen generic medications in most of the country's provinces. According to published reports, a group of premiers had reached a coordinated deal to reduce the prices their governments paid for six generic drugs, hoping to save the provinces nearly $100 million.

Biosimilar medicines have been approved and routinely prescribed in Europe for nearly seven years, and creation of a clear pathway for Food and Drug Administration review and approval of generic versions of bioengineered drugs was enshrined into law in the United States with the passage of the Patient Protection and Affordable Care Act nearly three years ago.